Literature DB >> 22183183

Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy.

Wolf Peter Hofmann1, Stefan Zeuzem.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22183183     DOI： 10.1038/nrgastro.2011.249

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  6 in total

1.  The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

Authors:  Stefan Zeuzem; Peter Buggisch; Kosh Agarwal; Patrick Marcellin; Daniel Sereni; Hartwig Klinker; Christophe Moreno; Jean-Pierre Zarski; Yves Horsmans; Hongmei Mo; Sarah Arterburn; Steven Knox; David Oldach; John G McHutchison; Michael P Manns; Graham R Foster
Journal:  Hepatology       Date:  2012-03       Impact factor: 17.425

2.  Boceprevir for untreated chronic HCV genotype 1 infection.

Authors:  Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

3.  Boceprevir for previously treated chronic HCV genotype 1 infection.

Authors:  Bruce R Bacon; Stuart C Gordon; Eric Lawitz; Patrick Marcellin; John M Vierling; Stefan Zeuzem; Fred Poordad; Zachary D Goodman; Heather L Sings; Navdeep Boparai; Margaret Burroughs; Clifford A Brass; Janice K Albrecht; Rafael Esteban
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

4.  Telaprevir for retreatment of HCV infection.

Authors:  Stefan Zeuzem; Pietro Andreone; Stanislas Pol; Eric Lawitz; Moises Diago; Stuart Roberts; Roberto Focaccia; Zobair Younossi; Graham R Foster; Andrzej Horban; Peter Ferenci; Frederik Nevens; Beat Müllhaupt; Paul Pockros; Ruben Terg; Daniel Shouval; Bart van Hoek; Ola Weiland; Rolf Van Heeswijk; Sandra De Meyer; Don Luo; Griet Boogaerts; Ramon Polo; Gaston Picchio; Maria Beumont
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

5.  Telaprevir for previously untreated chronic hepatitis C virus infection.

Authors:  Ira M Jacobson; John G McHutchison; Geoffrey Dusheiko; Adrian M Di Bisceglie; K Rajender Reddy; Natalie H Bzowej; Patrick Marcellin; Andrew J Muir; Peter Ferenci; Robert Flisiak; Jacob George; Mario Rizzetto; Daniel Shouval; Ricard Sola; Ruben A Terg; Eric M Yoshida; Nathalie Adda; Leif Bengtsson; Abdul J Sankoh; Tara L Kieffer; Shelley George; Robert S Kauffman; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

6.  Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.

Authors:  Stefan Zeuzem; Tarik Asselah; Peter Angus; Jean-Pierre Zarski; Dominique Larrey; Beat Müllhaupt; Ed Gane; Marcus Schuchmann; Ansgar Lohse; Stanislas Pol; Jean-Pierre Bronowicki; Stuart Roberts; Keikawus Arasteh; Fabien Zoulim; Markus Heim; Jerry O Stern; George Kukolj; Gerhard Nehmiz; Carla Haefner; Wulf Otto Boecher
Journal:  Gastroenterology       Date:  2011-09-16       Impact factor: 22.682
  6 in total
  3 in total

Review 1.  Impact of host and virus genome variability on HCV replication and response to interferon.

Authors:  Cameron J Schweitzer; T Jake Liang
Journal:  Curr Opin Virol       Date:  2013-07-06       Impact factor: 7.090

Review 2.  Innate immune cell networking in hepatitis C virus infection.

Authors:  Banishree Saha; Gyongyi Szabo
Journal:  J Leukoc Biol       Date:  2014-07-07       Impact factor: 4.962

3.  Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.

Authors:  Georg Dultz; Martin Seelhof; Eva Herrmann; Martin-Walter Welker; Mireen Friedrich-Rust; Gerlinde Teuber; Bernd Kronenberger; Michael von Wagner; Johannes Vermehren; Christoph Sarrazin; Stefan Zeuzem; Wolf Peter Hofmann
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.